Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Current Leases (2019 - 2023)

Historic Current Leases for Marker Therapeutics (MRKR) over the last 5 years, with Q1 2023 value amounting to $665082.0.

  • Marker Therapeutics' Current Leases fell 276.14% to $665082.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $665082.0, marking a year-over-year decrease of 276.14%. This contributed to the annual value of $577198.0 for FY2022, which is 697.71% down from last year.
  • Per Marker Therapeutics' latest filing, its Current Leases stood at $665082.0 for Q1 2023, which was down 276.14% from $577198.0 recorded in Q4 2022.
  • In the past 5 years, Marker Therapeutics' Current Leases ranged from a high of $738389.0 in Q2 2022 and a low of $189791.0 during Q1 2019
  • For the 5-year period, Marker Therapeutics' Current Leases averaged around $441696.5, with its median value being $473077.0 (2021).
  • Per our database at Business Quant, Marker Therapeutics' Current Leases surged by 13450.24% in 2020 and then plummeted by 1567.07% in 2022.
  • Marker Therapeutics' Current Leases (Quarter) stood at $204132.0 in 2019, then skyrocketed by 90.46% to $388792.0 in 2020, then soared by 59.59% to $620490.0 in 2021, then decreased by 6.98% to $577198.0 in 2022, then grew by 15.23% to $665082.0 in 2023.
  • Its Current Leases was $665082.0 in Q1 2023, compared to $577198.0 in Q4 2022 and $490449.0 in Q3 2022.